Reata Pharmaceuticals Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 349
Employees
  • Stock Symbol
  • RETA
Stock Symbol
  • Share Price
  • $27.80
  • (As of Thursday Closing)

Reata Pharmaceuticals General Information

Description

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Contact Information

Formerly Known As
Reata Discovery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 5320 Legacy Drive
  • Plano, TX 75024
  • United States
+1 (972) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Reata Pharmaceuticals Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.80 $26.88 $20.23 - $153.41 $1.01B 36.5M 671K -$8.35

Reata Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 738,367 246,440 3,886,366 6,592,799
Revenue 11,459 11,490 9,019 26,517
EBITDA (252,633) (243,559) (235,093) (284,281)
Net Income (303,773) (297,386) (247,752) (290,170)
Total Assets 679,868 735,016 857,598 682,420
Total Debt 141,587 136,033 5,323 155,017
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Reata Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.

Request a free trial

Reata Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.

Request a free trial

Reata Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commerci
Biotechnology
Plano, TX
349 As of 2021
00.000
000000000 00.000

00000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000

00000000

scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000000000000
Shelton, CT
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reata Pharmaceuticals Competitors (89)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Catalyst Biosciences Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
0000000000000 Corporation Shelton, CT 00 000.00 000000000 000.00
0000000 Venture Capital-Backed Hannover, Germany 00 00000 00000000000 00000
00000000 Venture Capital-Backed New Haven, CT 00 00000 00000000 00000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
You’re viewing 5 of 89 competitors. Get the full list »

Reata Pharmaceuticals Patents

Reata Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210040142-A1 C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof Pending 19-Jul-2019 0000000000
US-20210147380-A1 Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith Pending 20-Jun-2018 0000000000
EP-3810141-A1 Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith Pending 20-Jun-2018 0000000000
AU-2019286531-A1 Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma Pending 15-Jun-2018 0000000000
CA-3103726-A1 Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma Pending 15-Jun-2018 C07D231/54
To view Reata Pharmaceuticals’s complete patent history, request access »

Reata Pharmaceuticals Executive Team (19)

Name Title Board Seat Contact Info
Warren Huff JD Founder, Chief Executive Officer & President
Manmeet Soni Chief Financial Officer, Finance & Chief Operating Officer, Operations
Joel Proksch Ph.D Chief Development Officer & Senior Vice President, Regulatory
Steve Harman Chief Human Resources Officer & Vice President
James Rouse Vice President & Chief Information Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Reata Pharmaceuticals Board Members (12)

Name Representing Role Since
Jack Nielsen Self Board Member 000 0000
Martin Edwards MD Self Board Member 000 0000
R. Kent McGaughy Jr. Self Board Member 000 0000
Shamim Ruff Reata Pharmaceuticals Board Member 000 0000
William McClellan Jr. Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Reata Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reata Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.

Request a free trial